RHEUMAI is seeking an initial US$110,000–115,000 to advance two pharmacogenomics research programs in Mexico: STORM and STORM-APS. The investment would fund a defined next step: moving from computational research and protocol development into patient recruitment, genotyping and prospective validation. Led by Dr. Erick Adrián Zamora-Tehozol, a practicing rheumatologist in Mexico, these programs address questions arising directly from clinical care: variation in treatment response, drug toxicity and recurrent thrombosis despite apparently adequate therapy. @DrErickZamora1 and our cutting edge AI expert @thetokendad_, a biochemical engineer and very experienced hacker Our starting point is an existing STORM computational framework integrating regional ancestry, published pharmacogenomic evidence and Monte Carlo simulation. The next task is to test those predictions against observed patient data. STORM | Mexican rheumatology pharmacogenomics Proposed pilot: • 50 participants from a Maya–Mestizo rheumatology cohort. • Approximately 30 genes and 45–50 variants. • Targeted genotyping using MassARRAY or an equivalent platform. • Estimated six-month pilot. • Initial budget: US$10,300–14,650. We will compare predicted and observed variant frequencies and begin assessing relationships with treatment response and adverse effects. The subsequent validation phase would expand the cohort to 200 participants in total, incorporating molecular ancestry and prospective clinical outcomes. The estimated combined budget for both STORM phases is US$41,000–53,000. openlabs.bio.xyz/post/583abd… STORM-APS | Understanding antithrombotic treatment failure Proposed pilot: • 100 adults with thrombotic antiphospholipid syndrome. • Multicenter, prospective observational design. • Approximately 20–30 pharmacogenetic variants. • Integration of drug exposure, coagulation or platelet-function testing, adherence and clinical phenotype. • Planned assessment of recurrent thrombosis over 24 months. • Estimated initial pilot budget: US$99,600. The pilot will establish feasibility, variant prevalence and preliminary effect estimates to inform definitive validation. Patients remain on physician-selected treatment; exploratory genetic findings will not dictate prescribing. openlabs.bio.xyz/post/497167… Together, the initial pilot budgets total US$109,900–114,250. These are planning estimates, subject to institutional quotations and final protocol costing. What would this funding produce? A population-specific research dataset, evidence to recalibrate STORM, feasibility data for STORM-APS, and a stronger basis for larger validation studies and institutional partnerships. We propose milestone-based funding, with progress assessed against ethics approval, site readiness, recruitment, genotyping quality and prespecified analyses. We invite @BioProtocol and the @openlabsbio community to evaluate RHEUMAI for research funding and collaboration. We are seeking laboratory partners, participating centers and support for the next measurable stage of development. The opportunity is concrete: help build the Mexican patient evidence these models need to become clinically credible. RHEUMAI | Clinical questions. Testable models. Prospective evidence.